Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Genfit (OTC: GNFTF).

Full DD Report for GNFTF

You must become a subscriber to view this report.


Recent News from (OTC: GNFTF)

Novartis In Liver Diseases NASH And PBC: A Look At The Bright Side
There can be no greater gift than that of giving one’s time and energy to help others without expecting anything in return. —Nelson Mandela Novartis AG (NVS) is a Swiss (Basel, Switzerland) multibillion biopharmaceutical company with a market cap of $178B and a broad the...
Source: SeekingAlpha
Date: May, 17 2018 14:35
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf...
Source: SeekingAlpha
Date: May, 15 2018 10:00
Lipotoxicity And NASH: Gilead's Actions Speak Louder Than Words
I never lose. I either win or learn. —Nelson Mandela Gilead Sciences (GILD) is a multibillion ($89B market cap) biopharmaceutical company that has and is still revolutionizing the infectious disease market with innovative anti-viral therapies for HIV/AIDS, Hep B and C. It seem...
Source: SeekingAlpha
Date: May, 09 2018 11:08
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Conatus Falls On Phase 2 Data, But There Is More To The Story
Recently, Conatus Pharmaceuticals (CNAT) announced results for its phase 2b POLT-HCV-SVR study. What I must say about these results after having looked at them is that they were in the middle in terms of efficacy. The middle being that they weren't a complete failure or a complete success ov...
Source: SeekingAlpha
Date: April, 06 2018 11:36
Key events next week - healthcare
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 06 2018 07:14
Genfit - Integrated Strategy For The Management Of NASH Offers Upside Potential
Editor's note: Seeking Alpha is proud to welcome Kailyn Hui as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Genfit ( GNFTF...
Source: SeekingAlpha
Date: April, 05 2018 12:51
MediciNova Soars After NASH Study Stopped Early Due Too Extremely Positive Outcome
Recently, MediciNova ( MNOV ) announced that it had stopped its phase 2 NASH/NAFLD study early due too extremely positive efficacy achieved in an interim analysis. It met the primary endpoint of the study, and thus the company terminated the study early so that it can advance it immediat...
Source: SeekingAlpha
Date: April, 03 2018 12:01
Genfit: Valuing Elafibranor's Commercial Potential
In a recent article, we discussed what makes Genfit’s ( OTCPK:GNFTF ) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranor’s mechanism of action and the potential it has shown in clinic...
Source: SeekingAlpha
Date: March, 30 2018 12:31
Genfit: Why Is This One Of The Most Promising Players In NASH?
Non-alcoholic fatty liver disease or NALFD is expected to become the next global epidemic (Sherif et al, 2015) . NAFLD is defined as accumulation of lipids inside the hepatocytes exceeding 5% of the weight of the liver and in the absence of liver disease etiologies such as chronic viral he...
Source: SeekingAlpha
Date: March, 29 2018 02:09

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-14N/A26.6664N/AN/A0
2018-08-1327.3726.666427.5526.61800
2018-08-1027.9227.8027.9227.80700
2018-08-09N/A28.15N/AN/A0
2018-08-08N/A28.15N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-071,0002,10047.6190Short
2018-07-2650060083.3333Short
2018-07-251010100.0000Short
2018-07-20700700100.0000Short
2018-07-17358541.1765Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GNFTF.


About Genfit (OTC: GNFTF)

Logo for Genfit (OTC: GNFTF)

Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.

 

Contact Information

 

 

Current Share Structure

     



    Daily Technical Chart for (OTC: GNFTF)

    Daily Technical Chart for (OTC: GNFTF)


    Stay tuned for daily updates and more on (OTC: GNFTF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: GNFTF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GNFTF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GNFTF and does not buy, sell, or trade any shares of GNFTF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/